Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen

Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen

Source: 
Motley Fool
snippet: 

Swiss drugmaker Novartis's (NYSE: NVS) $9.7 billion takeover of The Medicines Company (NASDAQ: MDCO) gives the former ownership of an investigational cardiovascular drug called inclisiran. And that may mean trouble for Amgen (NASDAQ: AMGN) and its heart drug Repatha, which hasn't lived up to blockbuster hopes.